Zhang Xi

[Expert Profile] Zhang Xi, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in hematopoietic stem cell transplantation in China, working at the Hematology Medical Center, The Second Affiliated Hospital of Army Medical University (Xinqiao Hospital). He has long been dedicated to the clinical diagnosis, treatment, and scientific research of relapsed/refractory lymphoma and post-transplant complications, and is an important expert in the fields of transplantation and lymphoma in China.

[Education & Career] Professor Zhang Xi graduated from the Third Military Medical University (now Army Medical University), completed systematic clinical training at Xinqiao Hospital, and further studied at famous international hematology and transplantation centers. He has long served as Director of the Hematology Medical Center at Xinqiao Hospital, holding academic positions including member of the Hematology Branch of the Chinese Medical Association and the Hematologic Oncology Professional Committee of the Chinese Anti-Cancer Association. He has presided over national-level projects including key grants from the National Natural Science Foundation of China, and is a discipline leader in military hematology and transplantation.

[Areas of Expertise] Professor Zhang specializes in comprehensive treatment of relapsed/refractory lymphoma, hematopoietic stem cell transplantation for various leukemias and hematologic malignancies, and prevention and treatment of post-transplant complications (graft-versus-host disease, infection, relapse). He has extensive experience in haploidentical transplantation, "Beijing Protocol" technology promotion, and the application of novel cellular therapies such as CAR-T combined with transplantation. He excels at developing salvage treatment strategies for complex cases such as "post-transplant relapse" and "refractory lymphoma," helping numerous patients achieve second remission and long-term survival.

[Academic Achievements & Industry Contributions] Professor Zhang has led a series of clinical studies on relapsed/refractory lymphoma and post-transplant complications, systematically evaluating the application value of novel cellular therapies and targeted drugs in transplantation, with findings published in authoritative domestic and international journals. He has participated in the development of Chinese hematopoietic stem cell transplantation and lymphoma diagnosis and treatment guidelines and expert consensus statements, actively promoted standardized transplantation management, quality control system development, and clinical translation of new technologies, and led multi-center collaborative research, making important contributions to improving the treatment level of hematopoietic stem cell transplantation and refractory hematologic malignancies in China.

[Clinical Practice & Outstanding Contributions] For decades on the front lines of hematology and transplantation clinical work, Professor Zhang has led his team in completing a large number of highly difficult hematopoietic stem cell transplants, cumulatively treating tens of thousands of relapsed/refractory hematologic malignancy patients. Leading his team, he has established a comprehensive whole-course transplantation management system, successfully managing numerous difficult post-transplant complications. He has received multiple military honors and awards, and is deeply trusted by patients and respected by peers alike. He is an outstanding expert in the field of military hematology and transplantation.

[Honors & Reputation] Professor Zhang Xi serves as Director of the Hematology Medical Center at Xinqiao Hospital, Army Medical University, among other academic positions. He has presided over national-level projects including the National Key R&D Program, and is a senior expert in the fields of hematology and hematopoietic stem cell transplantation in China. He has profound expertise in the diagnosis and treatment of relapsed/refractory lymphoma and post-transplant complications. He has led research on precise prevention and treatment of post-transplant complications and cellular immunotherapy, promoted the standardized application of innovative technologies such as CAR-T in hematologic malignancies, and has research findings published in authoritative domestic and international journals. For decades on the clinical front lines, he has helped numerous relapsed/refractory hematologic malignancy patients gain a new lease on life, and is deeply trusted by patients and respected by peers alike.